Aktienanalyse wird geladen …
PODD · NASDAQ · Medical Devices · USA
135,83 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2,71 Mrd. | 247,1 Mio. | 3,48 $ | 71,89 Mio. | 0,5 Mio · 0,6 % | 2,5 Mio · 3,4 % | 71,6 % | 9,1 % | 5,25 $ | 0,87 $ | — |
| 2024 | 2,07 Mrd. | 418,3 Mio. | 5,78 $ | 73,89 Mio. | 0,5 Mio · 0,7 % | 0,3 Mio · 0,3 % | 69,8 % | 20,2 % | 4,13 $ | 0,94 $ | — |
| 2023 | 1,7 Mrd. | 206,3 Mio. | 2,94 $ | 73,63 Mio. | 0,4 Mio · 0,5 % | — | 68,4 % | 12,2 % | 0,95 $ | 0,66 $ | — |
| 2022 | 1,31 Mrd. | 4,6 Mio. | 0,07 $ | 69,91 Mio. | 0,3 Mio · 0,4 % | — | 61,7 % | 0,4 % | -0,06 $ | 0,59 $ | — |
| 2021 | 1,1 Mrd. | 16,8 Mio. | 0,24 $ | 68,58 Mio. | 0,3 Mio · 0,4 % | — | 68,5 % | 1,5 % | -2,62 $ | 0,50 $ | — |
| 2020 | 904,4 Mio. | 6,8 Mio. | 0,10 $ | 65,95 Mio. | 0,3 Mio · 0,4 % | — | 64,4 % | 0,8 % | -0,68 $ | 0,54 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 801,7 Mio. | 95 Mio. | 1,37 $ | 69,4 Mio. | 70,2 % | 11,9 % | 0,81 $ |
| Q1 2026 | 761,7 Mio. | 91,1 Mio. | 1,30 $ | 70,2 Mio. | 69,5 % | 12 % | 1,27 $ |
| Q4 2025 | 783,7 Mio. | 101,6 Mio. | 1,41 $ | 70,67 Mio. | 72,6 % | 13 % | 0,67 $ |
| Q3 2025 | 706,3 Mio. | 87,6 Mio. | 1,24 $ | 70,66 Mio. | 72,2 % | 12,4 % | 1,42 $ |
| Q2 2025 | 649,1 Mio. | 22,5 Mio. | 0,32 $ | 70,65 Mio. | 69,7 % | 3,5 % | 2,52 $ |
| Q1 2025 | 569 Mio. | 35,4 Mio. | 0,48 $ | 74,11 Mio. | 71,9 % | 6,2 % | 0,69 $ |
| Q4 2024 | 597,5 Mio. | 100,7 Mio. | 1,40 $ | — | 72,1 % | 16,9 % | 1,31 $ |
| Q3 2024 | 543,9 Mio. | 77,5 Mio. | 1,05 $ | 73,95 Mio. | 69,3 % | 14,3 % | 1,10 $ |
How Is Insulet's Stock Performance Compared to Other Medical Devices Stocks?
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
BCSM Exits Insulet Corporation (PODD), Maintains Watchlist Status
Beta Bionics’ insulin patch pump gets FDA nod
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
Artisan Sold Insulet (PODD) Due to Competition Concerns
Insulet Corporation is a medical device company focused on insulin delivery and diabetes management. Its flagship Omnipod platform includes wearable, tubeless insulin management systems designed to deliver continuous insulin without traditional pump tubing or multiple daily injections. The product line includes Omnipod 5, Omnipod DASH, and the Classic Omnipod, along with related pods, controllers, and diabetes management software that support day-to-day glucose control. Insulet also works with selected partners to adapt its Pod technology for the subcutaneous delivery of non-insulin therapies in other medical areas. Headquartered in Acton, Massachusetts, Insulet serves patients and healthcare providers across multiple international markets through direct sales and distribution channels.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest PODD und jede andere Aktie unbegrenzt.